Nivolumab in Esophageal Squamous-Cell Carcinoma.
作者信息
Ozer Muhammet, Sahin Ilyas
机构信息
Capital Health Regional Medical Center, Trenton, NJ.
University of Florida Health Cancer Center, Gainesville, FL
出版信息
N Engl J Med. 2022 May 19;386(20):1958-1959. doi: 10.1056/NEJMc2202880.
PMID:35584166
Abstract
摘要
相似文献
1
Nivolumab in Esophageal Squamous-Cell Carcinoma.纳武利尤单抗用于食管鳞状细胞癌
N Engl J Med. 2022 May 19;386(20):1958-1959. doi: 10.1056/NEJMc2202880.
2
Nivolumab in Esophageal Squamous-Cell Carcinoma.纳武利尤单抗治疗食管鳞状细胞癌
N Engl J Med. 2022 May 19;386(20):1959-1961. doi: 10.1056/NEJMc2202880.
3
Nivolumab in Esophageal Squamous-Cell Carcinoma.纳武利尤单抗治疗食管鳞状细胞癌
N Engl J Med. 2022 May 19;386(20):1959. doi: 10.1056/NEJMc2202880.
4
Nivolumab in Esophageal Squamous-Cell Carcinoma. Reply.纳武利尤单抗治疗食管鳞状细胞癌。回复。
N Engl J Med. 2022 May 19;386(20):1961. doi: 10.1056/NEJMc2202880.
5
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.纳武利尤单抗治疗日本食管癌患者的长期疗效和应答预测因素分析。
Cancer Sci. 2020 May;111(5):1676-1684. doi: 10.1111/cas.14380. Epub 2020 Apr 29.
6
Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.纳武利尤单抗二线治疗晚期食管鳞癌的成本效果分析。
Future Oncol. 2020 Jun;16(17):1189-1198. doi: 10.2217/fon-2019-0821. Epub 2020 May 14.
7
A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.免疫检查点抑制剂纳武利尤单抗联合抗血管生成药物安罗替尼治疗晚期食管鳞状细胞癌的病例报告
Medicine (Baltimore). 2019 Oct;98(40):e17164. doi: 10.1097/MD.0000000000017164.
8
Successful Management of Malignant Pericarditis Using Nivolumab for Metastatic Esophageal Squamous Cell Carcinoma.使用纳武单抗成功治疗转移性食管鳞状细胞癌所致恶性心包炎
Intern Med. 2024 Mar 1;63(5):677-680. doi: 10.2169/internalmedicine.2041-23. Epub 2023 Jul 19.
9
Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma.纳武利尤单抗联合化疗或伊匹木单抗治疗晚期食管鳞状细胞癌
Nat Rev Gastroenterol Hepatol. 2022 Apr;19(4):216. doi: 10.1038/s41575-022-00601-1.
10
Emerging data on nivolumab for esophageal squamous cell carcinoma.纳武利尤单抗治疗食管鳞癌的新数据。
Expert Rev Gastroenterol Hepatol. 2021 Aug;15(8):845-854. doi: 10.1080/17474124.2021.1948836. Epub 2021 Jul 12.
引用本文的文献
1
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8T and tumor cells.靶向SRSF1通过对CD8T细胞和肿瘤细胞的双重作用改善癌症免疫疗法。
Signal Transduct Target Ther. 2025 Jan 22;10(1):25. doi: 10.1038/s41392-024-02118-2.
2
Immunological biomarkers and predictive model for recurrence of esophageal squamous cell carcinoma after combined immunotherapy and neoadjuvant chemotherapy.免疫疗法联合新辅助化疗后食管鳞状细胞癌复发的免疫生物标志物及预测模型
Am J Cancer Res. 2024 Oct 15;14(10):4896-4908. doi: 10.62347/ELRQ9964. eCollection 2024.
3
Deciphering Treg cell roles in esophageal squamous cell carcinoma: a comprehensive prognostic and immunotherapeutic analysis.解析调节性T细胞在食管鳞状细胞癌中的作用：一项全面的预后和免疫治疗分析。
Front Mol Biosci. 2023 Sep 28;10:1277530. doi: 10.3389/fmolb.2023.1277530. eCollection 2023.
Zotero 插件